Molecular Pathology of Large Cell Carcinoma and Its Precursors

Eleazar, Jennifer

doi:10.1007/978-0-387-72430-0_27

Cited by 2 publications

(3 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large cell carcinomas were included in the AD histology as “a significant proportion of large cell carcinoma have immunohistochemical, cytogenetic, mutational and gene expression profiles that overlap with adenocarcinomas, which may reflect a common cell of origin” (24). …”

Section: Methodsmentioning

confidence: 99%

Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials

Haaf

Rosmalen

Koning

2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Implementing optimal lung cancer screening programs requires knowledge of the natural history and detectability of lung cancer. This information can be derived from the results of clinical trials with the aid of microsimulation models. Methods Data from the Surveillance Epidemiology and End Results (SEER) program and individual-level data from the National Lung Screening Trial (NLST) and the Prostate, Lung, Colon and Ovarian Cancer Screening trial (PLCO) were used to investigate the sensitivity (by histology and stage) of computed tomography (CT) and chest radiography (CXR) and the mean preclinical sojourn time (MPST) of lung cancer (by gender, histology and stage). The MISCAN-Lung model was used to reproduce the lung cancer incidence by method of detection (clinically or screen-detected), gender, histology and stage in both trials and SEER, by calibrating CT and CXR sensitivity and natural history parameters. Results CT sensitivity ranges from 8.83%–99.35% and CXR sensitivity from 2.51%–97.31%, depending on histology and stage. CT sensitivity for stage IA is more than threefold higher compared to CXR, for all histologies. The total MPST estimates for lung cancer progressing through preclinical stages IA to IV ranges from 3.09–5.32 years for men and 3.35–6.01 years for women. The largest difference in total MPST between genders was estimated for adenocarcinoma. Conclusions We estimate longer MPSTs for lung cancer compared to previous research, suggesting a greater window of opportunity for lung cancer screening. Impact This study provides detailed insights into the natural history of lung cancer and CT screening effectiveness.

show abstract

Section: Methodsmentioning

confidence: 99%

Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials

Haaf

Rosmalen

Koning

2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Large cell carcinomas are poorly differentiated carcinomas that can demonstrate features of AC (most frequent), SqCC, or neuroendocrine differentiation when examined by immunohistochemistry, electron microscopy, or molecular methods [55].…”

Section: Molecular Pathogenesismentioning

confidence: 99%

“…55 Pulmonary tuberculosis. This sagittal cut section of lung reveals a remarkable necrotic cavity in the upper lobe of progressive fibrocavitary disease.…”

mentioning

confidence: 99%

Molecular Basis of Pulmonary Disease

Farver¹,

Zander²

2009

Molecular Pathology

View full text Add to dashboard Cite

Molecular Pathology of Large Cell Carcinoma and Its Precursors

Cited by 2 publications

References 73 publications

Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials

Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials

Molecular Basis of Pulmonary Disease

Contact Info

Product

Resources

About